- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01027624
Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia (CEPHEUS)
April 14, 2011 updated by: AstraZeneca
Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia.
This is a multi-centre survey of patients who are currently on lipid lowering pharmacological treatment in South Africa.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Johannesburg, South Africa
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Multi-centre survey of patients who are currently on lipid-lowering pharmacological treatment in South Africa.
Description
Inclusion Criteria:
- Subject must be 18 years of age or older of either gender or race.
- Subject must provide informed consent and comply with the survey procedures.
- Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Exclusion Criteria:
- Subjects who are unwilling or unable to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Hyperchlesterolaemia
Participants undertreated with hypercholesterolaemia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III
|
Secondary Outcome Measures
Outcome Measure |
---|
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III
|
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to the Fourth Joint European Task Force Guidelines/South African Guidelines in primary/secondary prevention patients, patients with metabolic syndrome
|
Proportion of patients on lipid-lowering pharmacological treatment reaching the non HDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III Guidelines
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Prof F Raal, National Co-ordinator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
December 4, 2009
First Submitted That Met QC Criteria
December 4, 2009
First Posted (Estimate)
December 8, 2009
Study Record Updates
Last Update Posted (Estimate)
April 15, 2011
Last Update Submitted That Met QC Criteria
April 14, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-CZA-DUM-2009/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Undertreatment of Hypercholesterolaemia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHypercholesterolaemiaFrance, Belgium, Netherlands
-
AstraZenecaTerminatedHypercholesterolaemiaUnited Kingdom
-
AmgenTerminatedPregnancy | HypercholesterolaemiaBelgium, Denmark, Italy, Czechia, United Kingdom, Australia, Austria, Greece, Switzerland, Netherlands, Spain, Sweden, Slovakia, Norway
-
AstraZenecaWithdrawnPrimary Hypercholesterolaemia
-
AkesoAD Pharmaceuticals Co., Ltd.Completed
-
GlaxoSmithKlineCompleted
-
AstraZenecaCompletedHypercholesterolaemiaBosnia and Herzegovina
-
AstraZenecaCompleted
-
AstraZenecaCompletedHypercholesterolaemiaGreece